MedTrace Logo

Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy.

NCT04858880 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 374

Last updated 2025-09-16

No results posted yet for this study

Summary

A randomized phase III trial to study the effect of adding lymph node irradiation in patients with poor prostate-specific antigen (PSA) response during salvage radiotherapy for biochemical recurrence (0.15 ≤ PSA \<0.70 ng/ml) after prostatectomy.

Conditions

Interventions

RADIATION

Radiation to the prostate bed with or without addition of radiation of lymph node irradiation.

Radiation to the prostate bed with or without addition of radiation of lymph node irradiation (non responders). Patients with PSA response continues radiotherapy as initially planned, and are not followed according to the study protocol, only according to clinical practice.

Sponsors & Collaborators

  • Lund University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-09
Primary Completion
2030-04-30
Completion
2030-04-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04858880 on ClinicalTrials.gov